An Advanced TAVI Design
The CoreValve Platform was designed specifically to meet the clinical needs of your TAVI patients.
Approved for Valve-In-Bioprosthetic Valve
Over the last 10 years, the majority of surgically implanted aortic valves have been bioprosthetic. With a life expectancy of 10-20 years, the number of patients requiring redo surgery for failed bioprostheses is expected to increase. CoreValve and CoreValve Evolut provide options for heart teams who treat patients at high operative risk for redo surgery.
Over 25% Larger Potential Orifice Area
Supra-annular design maximizes blood flow. In a comparison, CoreValve has a larger potential orifice area when implanted in a degenerative surgical bioprosthesis.1
Lowest Post-Procedural Gradients
CoreValve demonstrates the lowest rate of post-procedural gradients in the Global Valve-in-Valve Registry.2
- Medtronic Data on File. Comparison between CoreValve and SAPIEN XT in surgical bioprosthesis.
- Danny Dvir on behalf of the Global Valve-in-Valve Registry Investigators. Transcatheter Aortic Valve Implantation for the Treatment of Degenerative Bioprosthetic Surgical Valves: Results from the Global Valve-in-Valve Registry. Presented at TCT 2012. Miami, Florida. October 23, 2012.